Overview

L-Annamycin for Injection in Combination With Cytarabine Injection as Second Line Therapy for Remission Induction in Adult Subjects With Refractory/Relapsed AML

Status:
RECRUITING

Trial end date:
2030-08-01

Target enrollment:

Participant gender:

Summary

This pivotal phase 2/3, multi-center, adaptive design study of L-Annamycin for Injection in combination with Cytarabine Injection as second line therapy for remission induction in adult subjects with refractory/relapsed AML is divided into two parts, Part A and Part B.

Phase:

PHASE2

Details

Lead Sponsor:

Moleculin Biotech, Inc.

Treatments:

Cytarabine
Injections